1. Articles in category: Information

    1-24 of 211 1 2 3 4 5 6 7 8 9 »
    1. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Proc Natl Acad Sci U S A. 2017 Jul 10;:

      Authors: Westerlund I, Shi Y, Toskas K, Fell SM, Li S, Surova O, Södersten E, Kogner P, Nyman U, Schlisio S, Holmberg J

      Read Full Article
      Mentions: Treatment MYCN
    2. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

      Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

      Cancer. 2017 Jul 11;:

      Authors: Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG

      Read Full Article
      Mentions: Staging COG MYCN
    3. Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.

      Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jul 07;:

      Authors: Stone A, Novetsky Friedman D, Worgall S, Kushner BH, Wolden S, Modak S, LaQuaglia MP, Wu X, Cheung NK, Sklar CA

      Abstract BACKGROUND: Children with high-risk neuroblastoma are exposed to multimodality therapies early in life and survivors confront late therapy-related toxicities.

      Read Full Article
    4. Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      J Pediatr Hematol Oncol. 2017 Jul 03;:

      Authors: Ari P, Kars M, Meany H, Pestieau S

      Abstract Children with high-risk neuroblastoma are currently treated with a chimeric monoclonal antibody against GD2 ganglioside (chimeric 14.18). The treatment improves survival but causes transient neuropathic pain-like syndrome.

      Read Full Article
      Mentions: Antibody Treatment
    5. 11q deletion in neuroblastoma: a review of biological and clinical implications.

      11q deletion in neuroblastoma: a review of biological and clinical implications.

      Mol Cancer. 2017 Jun 29;16(1):114

      Authors: Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause F

      Abstract Deletion of the long arm of chromosome 11 (11q deletion) is one of the most frequent events that occur during the development of aggressive neuroblastoma. Clinically, 11q deletion is associated with higher disease stage and decreased survival probability.

      Read Full Article
    6. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Pediatr Hematol Oncol. 2017 Jun 29;:1-21

      Authors: Ahmed AA, Zhang L, Reddivalla N, Hetherington M

      Abstract Neuroblastoma is the most common extracranial solid tumor in childhood accounting for 8-10% of all childhood malignancies. The tumor is characterized by a spectrum of histopathologic features and a heterogeneous clinical phenotype.

      Read Full Article
      Mentions: MYCN
    7. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.

      The findings lay the groundwork for developing more targeted treatments for...

      Read Full Article
      Mentions: MYCN
    8. Potential for more targeted treatments of neuroblastoma tumors

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    9. Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma.

      Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma.

      Oncotarget. 2017 May 30;:

      Authors: Morandi F, Barco S, Stigliani S, Croce M, Persico L, Lagazio C, Scuderi F, Belli ML, Montera M, Cangemi G, Pozzi S, Rigo V, Scaruffi P, Amoroso L, Erminio G, Pistoia V, Ferrini S, Corrias MV

      Read Full Article
    10. New research points to potential for more targeted treatments of neuroblastoma tumors

      New research points to potential for more targeted treatments of neuroblastoma tumors

      ( University of Chicago Medical Center ) Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    11. CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      Oncotarget. 2017 Jun 13;:

      Authors: Chikaraishi K, Takenobu H, Sugino RP, Mukae K, Akter J, Haruta M, Kurosumi M, Endo TA, Koseki H, Shimojo N, Ohira M, Kamijo T

      Abstract BACKGROUND: Despite the use of aggressive therapy, survival rates among high-risk neuroblastoma (NB) patients remain poor. Cancer stem cells (CSCs) are considered to be critically involved in the recurrence and metastasis of NB and are isolated as NB spheres.

      Read Full Article
      Mentions: Metastasis
    12. The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.

      The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.

      Cancer Lett. 2017 Jun 07;:

      Authors: Kollareddy M, Sherrard A, Park JH, Szemes M, Gallacher K, Melegh Z, Oltean S, Michaelis M, Cinatl J, Kaidi A, Malik K

      Read Full Article
      Mentions: ALK MYCN
    13. Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

      Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

      Oncotarget. 2017 May 23;:

      Authors: Li Y, Ohira M, Zhou Y, Xiong T, Luo W, Yang C, Li X, Gao Z, Zhou R, Nakamura Y, Kamijo T, Kaneko Y, Taketani T, Ueyama J, Tajiri T, Zhang H, Wang J, Yang H, Yin Y, Nakagawara A

      Read Full Article
      Mentions: ALK
    14. Chronic health conditions among long-term survivors of childhood cancer decrease over three decades as treatments improve

      Chronic health conditions among long-term survivors of childhood cancer decrease over three decades as treatments improve

      MEMPHIS, Tenn., June 2, 2017 /PRNewswire/ -- Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CC...

      Read Full Article
      Mentions: Treatment
    15. Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

      Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.

      J Pediatr Hematol Oncol. 2017 May 23;:

      Authors: Armstrong AE, Danner-Koptik K, Golden S, Schneiderman J, Kletzel M, Reichek J, Gosiengfiao Y

      Read Full Article
      Mentions: Chemotherapy
    16. Neuroblastoma Presenting as Non-MIBG-Avid Widespread Soft Tissue Metastases Without Bone Involvement Revealed by Fdg PET/CT Imaging.

      Neuroblastoma Presenting as Non-MIBG-Avid Widespread Soft Tissue Metastases Without Bone Involvement Revealed by FDG PET/CT Imaging.

      Clin Nucl Med. 2017 May 19;:

      Authors: Tolboom N, Servaes SE, Zhuang H

      Abstract Soft tissue metastases from neuroblastoma very rarely occur without concurrent osseous metastases. We report 1 case of non-MIBG-avid, high-risk neuroblastoma in a pediatric patient who had widespread soft tissue metastases without concurrent osseous lesion on FDG PET/CT imaging.

      Read Full Article
      Mentions: Imaging MIBG
    17. Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.

      "Incorporation of high-dose 131I-MIBG treatment into tandem HDCT/auto-SCT could reduce short- and long-term toxicities associated with TBI, without jeopardizing the survival rate."

      Read Full Article
    18. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Phase III

      Treatment

      Not yet active

      365 days to 30 years

      ANBL1531

      NCI-2016-01734, NCT03126916

      This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells.

      Read Full Article
      Mentions: Treatment INRG ALK
    1-24 of 211 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) COG
  4. Researches in the News

    1. (4 articles) MYCN
    2. (2 articles) ALK
    3. (1 articles) Antibody
    4. (1 articles) PHOX2B
  5. General Informations in the News

    1. (2 articles) Treatment
    2. (1 articles) Staging